Top Performing IPO for 2021 & 2022; $RGC The ye
Post# of 24950
(Total Views: 210)
Posted On: 12/21/2022 5:07:07 AM
Top Performing IPO for 2021 & 2022; $RGC
The year 2021 has seen a huge number of 1,035 companies taking IPO in the US market; where the huge piece of the listings (35%) were in the biotech & healthcare sector. (A possible move by companies to ride on the Covid / Healthcare wave; just thinking out loud).
The company which had the largest gains since IPO does not turn heads when mentioned nor is it a name you seen in ads on television or YouTube. But this company was in the sight of many hedge funds and traders for a while period.
Regencell Bioscience (NASDAQ:[RGC](https://www.benzinga.com/stock/RGC#NASDAQ)). RGC is the top performing stock of all 2021 IPOs according to stockanalysis.com/ipos/2021/. As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.
[A June 2022 article]( https://www.benzinga.com/general/biotech/22/0...s-short-i) mentioned that RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.
For year 2022, the company which shot to the moon since IPO is AMTD Digital (NYSE:[HKD]) (https://www.benzinga.com/stock/HKD#NYSE)), a company founded by Mr. Li Ka-Shing’s Cheung Kong Group and Hutchison Whampoa in 2003. HKD’s IPO price was $7.80 and has gained over a staggering 9,000% since, closing at $742.00 on August 1, 2022.
Although RGC is the #1 performer of 2021 IPOs, this pales in comparison with the current performance of HKD. Astute traders who have an eye for forensic analysis in companies with low float and outsized short interest are indeed very happy.
Comparison between the 2 companies can be found in the article link shard at the end of page.
(https://www.benzinga.com/amp/content/28316977)
The year 2021 has seen a huge number of 1,035 companies taking IPO in the US market; where the huge piece of the listings (35%) were in the biotech & healthcare sector. (A possible move by companies to ride on the Covid / Healthcare wave; just thinking out loud).
The company which had the largest gains since IPO does not turn heads when mentioned nor is it a name you seen in ads on television or YouTube. But this company was in the sight of many hedge funds and traders for a while period.
Regencell Bioscience (NASDAQ:[RGC](https://www.benzinga.com/stock/RGC#NASDAQ)). RGC is the top performing stock of all 2021 IPOs according to stockanalysis.com/ipos/2021/. As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.
[A June 2022 article]( https://www.benzinga.com/general/biotech/22/0...s-short-i) mentioned that RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.
For year 2022, the company which shot to the moon since IPO is AMTD Digital (NYSE:[HKD]) (https://www.benzinga.com/stock/HKD#NYSE)), a company founded by Mr. Li Ka-Shing’s Cheung Kong Group and Hutchison Whampoa in 2003. HKD’s IPO price was $7.80 and has gained over a staggering 9,000% since, closing at $742.00 on August 1, 2022.
Although RGC is the #1 performer of 2021 IPOs, this pales in comparison with the current performance of HKD. Astute traders who have an eye for forensic analysis in companies with low float and outsized short interest are indeed very happy.
Comparison between the 2 companies can be found in the article link shard at the end of page.
(https://www.benzinga.com/amp/content/28316977)
(0)
(0)Scroll down for more posts ▼